Literature DB >> 2776824

Comparative pharmacokinetics of zidovudine (AZT) and its metabolite (G.AZT) in healthy subjects and HIV seropositive patients.

E Singlas1, J C Pioger, A M Taburet, S Colaneri, J P Fillastre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2776824     DOI： 10.1007/BF00637752

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  2 in total

1.  Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases.

Authors:  R W Klecker; J M Collins; R Yarchoan; R Thomas; J F Jenkins; S Broder; C E Myers
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

2.  Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography.

Authors:  S S Good; D J Reynolds; P de Miranda
Journal:  J Chromatogr       Date:  1988-09-23
  2 in total
  16 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors:  J P Fillastre; E Singlas
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

2.  Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection.

Authors:  B L Lee; S Safrin; V Makrides; J G Gambertoglio
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus.

Authors:  E Cañas; J Pachon; F Garcia-Pesquera; J R Castillo; P Viciana; J M Cisneros; M E Jimenez-Mejias
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

4.  The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients.

Authors:  J Sahai; K Gallicano; G Garber; I McGilveray; N Hawley-Foss; N Turgeon; D W Cameron
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

Review 5.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

6.  Pharmacokinetic interaction between rifampin and zidovudine.

Authors:  D M Burger; P L Meenhorst; C H Koks; J H Beijnen
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

7.  Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients.

Authors:  K Gallicano; J Sahai; E Ormsby; D W Cameron; A Pakuts; I McGilveray
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

8.  Absorption of zidovudine in patients with diarrhoea.

Authors:  G Zorza; L Beaugerie; A M Taburet; Y Le Quintrec; E Singlas
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 9.  Comparative pharmacokinetics of antiviral nucleoside analogues.

Authors:  G D Morse; M J Shelton; A M O'Donnell
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

10.  The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene.

Authors:  Nada Abla; Leslie W Chinn; Tsutomu Nakamura; Li Liu; Conrad C Huang; Susan J Johns; Michiko Kawamoto; Doug Stryke; Travis R Taylor; Thomas E Ferrin; Kathleen M Giacomini; Deanna L Kroetz
Journal:  J Pharmacol Exp Ther       Date:  2008-03-25       Impact factor: 4.030
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.